2022
Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.
Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.Peer-Reviewed Original ResearchMRI-ultrasound fusion biopsyNCCN risk classificationMRI-ultrasound fusionFusion biopsyLower riskActive surveillanceNCCN riskSystematic biopsyCore biopsyRisk classificationFirst-time biopsyInitial active surveillanceProportion of patientsMajority of patientsEra of MRIPrimary study objectiveProstate cancer risk classificationNCCN definitionsMedian PSASurveillance biopsiesBiopsy cohortRetrospective studySingle institutionProstate cancerBiopsy
2016
Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance.
Leapman M, Cowan J, Nguyen H, Cooperberg M, Carroll P. Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2016, 34: 124-124. DOI: 10.1200/jco.2016.34.2_suppl.124.Peer-Reviewed Original ResearchGenomic Prostate ScoreAdverse pathological findingsActive surveillanceProstate cancerRadical prostatectomyPathological findingsFavorable-risk prostate cancerIntermediate-risk prostate cancerIntermediate clinical riskNCCN risk classificationSerial prostate biopsyRisk prostate cancerSubsequent clinical outcomesTime of surgeryRT-PCR assaysPT3a diseaseDefinitive therapyIntermediate riskOncologic outcomesClinical outcomesAdverse pathologySerial biopsiesProstate biopsyMedian changeSerial changes